A novel phase 1 trial is investigating the combination of tagraxofusp and pacritinib in patients with myelofibrosis who have failed or cannot receive JAK1/2 inhibitor therapy, targeting a significant unmet need in this population.
Novartis announces closure of MorphoSys facilities in the US and Germany, affecting 330 jobs, following its $2.9 billion acquisition of the German biotech company.
Scemblix (asciminib) demonstrates favorable safety and tolerability in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) patients after 96 weeks, based on the Phase 3 ASC4FIRST study.
Emerging therapies like luspatercept, nuvisertib, and pelabresib show promise in addressing myelofibrosis symptoms and anemia, potentially improving patient outcomes.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.